Pharmacological Interventions in Hearing Disorders

Numerous pharmacological agents have demonstrated protection and/or rescue from noise-induced hearing loss (NIHL) and/or drug-induced hearing loss (DIHL) in preclinical studies around the world. Some have already progressed to clinical trials. Although none are yet approved for clinical use, it appears likely that in the future one or more of these agents will be available to treat or prevent DIHL or NIHL. Consequently, clinical audiologists and Speech–Language pathologists need to be aware of the agents being studied and their underlying mechanisms of protection.


NIHL is a rapidly growing public health concern. According to Yulia Carrol, evidence of NIHL exists in approximately one in four U.S. adults aged 20–69 years. Hearing loss leads to communication impairments that may have significant social and professional repercussions.

Either intense impulses ...

  • Loading...
locked icon

Sign in to access this content

Get a 30 day FREE TRIAL

  • Watch videos from a variety of sources bringing classroom topics to life
  • Read modern, diverse business cases
  • Explore hundreds of books and reference titles